argenx Unnatural Products Acquisition: Inside the $1.15B Bet on Oral Peptides
argenx will buy Unnatural Products for up to $1.15B ($550M upfront) to own an oral macrocyclic peptide platform. Terms, strategy, risks and market context.
Tag: argenx
Read More